Examkin

Question

Difficulty: HardInfectious Diseases

An intensivist is reviewing the microbiological data for a 48-year-old male patient on mechanical ventilation. The patient was admitted to the intensive care unit 8 days ago following a motor vehicle collision that resulted in severe head trauma. Three days ago, he developed a new fever of 39.2∘C39.2^\circ\text{C} (102.6∘F102.6^\circ\text{F}), thick endotracheal secretions, and worsening hypoxemia. A chest radiograph at that time revealed a new left lower lobe consolidation. He was empirically started on intravenous vancomycin, cefepime, and tobramycin for suspected ventilator-associated pneumonia (VAP).

Today, the patient is clinically improved. His temperature is 37.4∘C37.4^\circ\text{C} (99.3∘F99.3^\circ\text{F}), and his oxygen requirements have decreased. The endotracheal aspirate culture obtained prior to antibiotic initiation now shows:

- Heavy growth of *Pseudomonas aeruginosa*
- Moderate growth of *Candida albicans*
- No *Staphylococcus aureus* isolated

Antimicrobial susceptibility testing for the *Pseudomonas aeruginosa* isolate demonstrates susceptibility to cefepime, meropenem, piperacillin-tazobactam, and tobramycin. Blood cultures drawn at the time of the fever have remained sterile.

Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Discontinue vancomycin and tobramycin, and continue cefepimeAnswer
  2. B
    Discontinue vancomycin, and continue cefepime and tobramycin
  3. C
    Discontinue vancomycin and tobramycin, continue cefepime, and add fluconazole
  4. D
    Continue the current empiric regimen of vancomycin, cefepime, and tobramycin
  5. E
    Discontinue vancomycin and tobramycin, and switch cefepime to meropenem

Answer

Discontinue vancomycin and tobramycin, and continue cefepime
The correct approach for this clinically improving patient with ventilator-associated pneumonia (VAP) is to de-escalate the empiric antibiotic regimen to targeted monotherapy based on finalized culture and susceptibility results. First, vancomycin should be discontinued because no methicillin-resistant Staphylococcus aureus (MRSA) was isolated. Second, tobramycin can be discontinued; while double antipseudomonal coverage is appropriate for initial empiric therapy in patients at high risk for resistant organisms, definitive therapy should be narrowed to a single active agent (in this case, cefepime) to reduce the risk of nephrotoxicity. Finally, the isolation of Candida albicans from endotracheal secretions represents airway colonization. Candida is a normal commensal of the oropharynx, and treating it with antifungals in this setting is a common error in antimicrobial stewardship.

Step-by-Step Solution

1
Analyze the need for ongoing MRSA coverage.
The culture showed no growth of Staphylococcus aureus after 3 days.
Empiric MRSA coverage (vancomycin) should be discontinued when respiratory cultures do not isolate MRSA, in order to reduce nephrotoxicity.
2
Determine the optimal definitive therapy for the Pseudomonas isolate.
The isolate is susceptible to cefepime, which the patient is already receiving.
Once a Pseudomonas isolate is proven susceptible to a beta-lactam (cefepime), the second empiric agent (tobramycin) should be discontinued to de-escalate therapy.
3
Evaluate the clinical significance of Candida albicans in the respiratory tract.
Candida in endotracheal aspirates represents airway colonization.
Antifungal therapy is not indicated for Candida isolated from respiratory secretions, as invasive Candida pneumonia is exceptionally rare.

Key Concept

Antimicrobial de-escalation in VAP involves discontinuing unnecessary MRSA and double-antipseudomonal coverage once susceptibilities are known, and recognizing that respiratory Candida represents colonization.
Estimated Time:1m 30s
Rate this question

Topics

Infectious Diseases

More questions from this topic